Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.11 | 0.05 | 0.00 |
| FCF Yield | -3.77% | -3.99% | -1.99% | -7.12% |
| EV / EBITDA | 6.00 | -3.14 | -4.36 | -19.14 |
| Quality | ||||
| ROIC | -1.59% | -3.43% | -2.50% | -2.05% |
| Gross Margin | 0.00% | 0.65% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.27 | 0.46 | 0.19 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.55% | -9.55% | -100.00% | -100.00% |
| Free Cash Flow Growth | -0.48% | -83.25% | 72.95% | -442.29% |
| Safety | ||||
| Net Debt / EBITDA | -1.13 | 16.60 | 5.54 | 13.72 |
| Interest Coverage | 0.00 | -1.76 | 0.23 | -0.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,145.00 | -23.05 | -2,290.65 | 0.00 |